Clinical Trial Update: TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients [Phase 1]

View source ↗

Summary

Phase 1 study evaluating swallowability of uncoated 200 mg etravirine tablets in HIV-1 infected patients. The document reports on tablet acceptability in this p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Intelence (Etravirine)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV-Infections | Phase 1 | Status: COMPLETED